Community/Retail

FDA officials have approved onabotulinumtoxinA (BOTOX Cosmetic, Allergan) for its third indication for the temporary improvement in the appearance of moderate-to-severe forehead lines associated with frontalis muscle activity in adults.

According to an "FDA in Brief" report, officials with the FDA received an adverse event report on August 14, 2017, from a physician concerning a patient who was diagnosed postoperatively with bilateral hemorrhagic occlusive retinal vasculitis (HORV).

On September 29, 2017, the ASHP (American Society of Health-System Pharmacists) Board of Directors voted unanimously to approve the creation of an enhanced membership home for pharmacy technicians — the ASHP Pharmacy Technician Forum.

The Drug Quality and Security Act (DQSA) provides a framework for working with outsourcing facilities to meet federal regulatory standards.

This decision was made based on a review of available phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection, including elbasvir and grazoprevir (Zepatier).

Eliminating retroactive pharmacy payment reductions — or post point-of-sale pharmacy "DIR fees" — in Medicare Part D would save the federal government $3.4 billion over 10 years, according to a Wakely Consulting Group study released today by the National Community Pharmacists Association.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

A New Jersey company that sold injectable skin whitening and other beauty products has been ordered to stop selling and recall some of its products because they are unapproved new drugs that are potentially unsafe to consumers, according to the FDA's press release.